SynthesisBMC infectious diseases2025
Ciprofloxacin resistance in community and hospital-acquired urinary tract infections: a systematic review and meta-analysis from African population.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of antimicrobial resistance in acute community-acquired urinary tract infections in Sub-Saharan Africa: a systematic review.JAC-antimicrobial resistance · 2026Review
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the introduction of fluorinated derivatives (fluoroquinolones) in the 1980s, these agents, especially ciprofloxacin, have become standard treatment for various bacterial infections, including urinary tract infections (UTIs). Frequently, in developing countries UTIs are treated empirically due to limited capacity of the culture and sensitivity testing in most health facilities. Despite the high usage, there is a scarcity of data regarding ciprofloxacin resistance/susceptibility pattern among uropathogens isolated in Africa. This study aimed to conduct a systematic review to ascertain the rate of ciprofloxacin resistance among uropathogens in Africa and identify the most common fluoroquinolone-resistant uropathogens in the region.
methodsWe used the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines to search the PubMed, Embase and Scopus databases, as well as grey literature search, for articles reporting on the antibiotic susceptibility of uropathogens in African countries between January 2010 and December 2023.
resultsA total of 2940 articles were screened resulting to 44 relevant studies that were included, from three regions of Africa; East, West and North Africa. Majority of the studies were from East Africa (35/44; 79.5%) whilst North Africa contributed few numbers of studies (3/44; 6.8%). The overall rate of uropathogens resistant to ciprofloxacin in Africa was 34% (95%, CI = 0.27-0.40) which was from isolates obtained from various study populations, including the general population (24/44; 54.5%, pregnant women (8/44; 18.1%), children (7/44; 15.9%) and HIV infected individuals (5/44; 11.4%). Resistance to ciprofloxacin was high in North Africa (56%; 95% CI 0.27-0.85) compared to other African regions. Enterococci pathogens exhibited higher ciprofloxacin resistance, 47% (95% CI 0.21-0.75) compared to other bacteria isolates.
conclusionThis review has shown significant resistance of uropathogens to ciprofloxacin, which is often the primary treatment for urinary tract infections in numerous African countries. Variability in resistance patterns among countries highlights the pressing requirement for coordinated surveillance throughout the region and emphasizes the importance of tailored interventions based on the local data. It is essential to conduct regular epidemiological monitoring of antibiotic resistance and establish effective infection control and antimicrobial stewardship programs in the African regions.
trial registrationPROSPERO identification number: CRD42023471255.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.